Inactive structures of the vasopressin V2 receptor reveal distinct binding modes for Tolvaptan and Mambaquaretin toxin
Aurélien Fouillen, Julien Bous, Pierre Couvineau, Hélène Orcel, Charline Mary, Lucie Lafleur, Timothé Pierre, Christiane Mendre, Nicolas Gilles, Gunnar Schulte, Sébastien Granier, Bernard Mouillac
Abstract
Inhibitors of the arginine-vasopressin (AVP) V2 receptor (V2R) are key therapeutic compounds for treating hyponatremia or polycystic kidney diseases. Rational drug design based on experimental G protein-coupled receptor structures is a powerful avenue to develop better drugs. So far, the lack of inhibitor-bound V2R structures has impaired this strategy. Here we describe the cryo-electron microscopy structures of the V2R in complex with two selective inverse agonists, the non-peptide Tolvaptan (TVP) and the green mamba snake Mambaquaretin toxin (MQ1). Both ligands bind into the orthosteric binding site but with substantial differences. TVP binds deeper than MQ1, and directly contacts the toggle switch residue W2846.48 in the transmembrane domain 6. The Kunitz-fold toxin displays extensive contacts with extracellular and transmembrane residues. As anticipated from TVP and MQ1 pharmacological properties, both structures represent inactive V2R conformations. Their comparison with those of the active AVP-bound V2R reveals the molecular mechanisms modulating receptor activity. The mini-protein MQ1-bound V2R structure suggests a new pharmacology approach for treating water homeostasis and renal diseases. To help in the rational design of new compounds for treating hyponatremia and polycystic kidney disease, the authors solve cryo-EM structures of the G protein-coupled vasopressin type 2 receptor in its inactive state, bound to a small molecule or to a mini-protein from snake venom.